Study conduct in groups [Design Issues]

posted by Helmut Homepage – Vienna, Austria, 2015-02-02 14:08 (3701 d 09:33 ago) – Posting: # 14351
Views: 26,646

Hi Smitha,

please search the forum before posting. We discussed this issue numerous times before.

The FDA stated in letters to applicants (nothing in any guidance!):

If all of the following criteria are met, it may not be necessary to test for group effects in the model:
  • the clinical study takes place at one site;
  • all study subjects have been recruited from the same enrollment pool;
  • all of the subjects have similar demographics; and
  • all enrolled subjects are randomly assigned to treatment groups at study outset
In this latter case, the appropriate statistical model would include only the factors Sequence, Period, Treatment and Subject(nested within sequence).


I you want to avoid trouble with a statistical model incorporating a group-term (which might turn out to be significant by chance) I would go with 40 in your case.

No idea about the EMA.

Dif-tor heh smusma 🖖🏼 Довге життя Україна! [image]
Helmut Schütz
[image]

The quality of responses received is directly proportional to the quality of the question asked. 🚮
Science Quotes

Complete thread:

UA Flag
Activity
 Admin contact
23,409 posts in 4,921 threads, 1,669 registered users;
18 visitors (0 registered, 18 guests [including 8 identified bots]).
Forum time: 23:42 CET (Europe/Vienna)

Facts are meaningless. You could use facts to prove
anything that’s even remotely true!    Homer Simpson

The Bioequivalence and Bioavailability Forum is hosted by
BEBAC Ing. Helmut Schütz
HTML5